T1 hyperintensity in the brain after multiple intravenous injections of gadolinium-based contrast agents

Grobner T . Gadolinium - a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? Nephrol Dial Transplant 2006; 21: 1104–1108.

Marckmann P Skov L Rossen K . Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging. J Am Soc Nephrol 2006; 17: 359–2362.

Thomsen HS Nephrogenic systemic fibrosis and gadolinium-based contrast media. In: Thomsen HS Webb JAW (eds). Contrast Media: Safety Issues and ESUR Guidelines, 3rd edn. Heidelberg: Springer, 2014, pp. 201–217.

Chabanova E Logager VB Moller JM . Manganese based MR contrast agents: Formulation and Clinical applications. Open Drug Safety J 2011; 2: 29–38.

Kanda T Ishii K Kawaguchi H . High signal intensity in the dentate nucleus and globus pallidus on unenhanced T1-weighted MR images: relationship with increasing dose of a gadolinium-based contrast material. Radiology 2014; 270: 834–841.

Kanda T Osawa M Oba H . High signal intensity in dentate nucleus on unenhanced T1-weighted MR images: Association with linear versus macrocyclic gadolinium chelate administration. Radiology 2015; 275: 803–809.

Ramalho J Castillo M AlObaidy M . High signal intensity in globus pallidus and dentate nucleus on unenhanced T1-weighted MR images: Evaluation of two linear gadolinium-based contrast agents. Radiology 2015; 276: 836–844.

Radbruch A Weberling LD Kieslich PJ . Gadolinium retention in the dentate nucleus and globus pallidus is dependent on the class of contrast agent. Radiology 2015; 275: 783–791.

Adin ME Kleinberg L Zan VE . Hyperintense dentate nuclei on T1-weighted MRI: relation to repeat gadolinium administration. Am J Neuroradiol 2015; 36: 1859–1865.

Quattrocchi CC Mallio CA Errante Y . Gadodiamide and dentate nucleus T1 hyperintensity in patients with meningioma evaluated by multiple follow-up contrast-enhanced mangnetic resonance examinations with no systemic interval therapy. Invest Radiol 2015; 50: 470–472.

Roberts DR, Holden KR. Progressive increase of T1 signal intensity in the dentate nucleus and globus pallidus on unenhanced T1-weighted MR images in the pediatric brain exposed to multiple doses of gadolinium contrast. Brain Dev 2015. doi: 10.1016/j.braindev.2015.08.009.

Robert P Lehericy S Grand S . T1-weighted hypersignal in the deep cerebellar nuclei after repeated administrations of gadolinium-based contrast agents in healthy rats. Difference between linear and macrocyclic agents. Invest Radiol 2015; 50: 473–480.

Kanda T Kukusato T Matsuda M . Gadolinium-based contrast agent accumulates in the brain even in subjects without severe renal dysfunction: Evaluation of autopsy brain specimens with inductively coupled plasma mass spectroscopy. Radiology 2015; 276: 228–232.

McDonald RJ McDonald JS Kallmes DF . Intracranial gadolinium deposition after contrast-enhanced MR imaging. Radiology 2015; 275: 772–782.

Kanal E Tweedle MF . Residual or retained gadolinium: practical implications for radiologists and our patients. Radiology 2015; 276: 228–232.

Brunberg JA Kanal E Hirsch W . Chronic acquired hepatic failure: MR imaging of the brain at 1.5T. Am J Neuroradiol 1991; 12: 909–914.

Oikonomou A Chatzistefanou A Zezoz P . Basal ganglia hyperintensity on T1-weighted MRI in Rendu-Osler-Weber disease. J Magn Reson Imaging 2012; 35: 426–430.